Patients undergoing peripheral endovascular therapy for critical limb ischemia (CLI) have a higher risk for death and major limb amputation if they are on dialysis at the time of the procedure, according to a study published online July 24, 2015, in the Journal of Vascular Surgery. 

“These data may facilitate efforts to improve patient selection and, after further validation, enable risk-adjusted outcome reporting for CLI patients undergoing [peripheral intervention],” write Daniel J. Bertges, MD, of the University of Vermont Medical Center (Burlington, VT), and colleagues.

The investigators looked at data from the Vascular Study Group of New England (VSGNE) peripheral vascular intervention registry on 1,244 patients (mean age 70 years; 58% men) who underwent peripheral endovascular treatment for CLI between January 2010 and December 2011.

The primary indication for intervention was tissue loss in 71% and rest pain in 29%. Most patients had comorbidities, including a history of hypertension in 90%, prior or current smoking in 75%, and diabetes in 61%. Types of intervention were angioplasty alone, stenting, stent grafting, and atherectomy.

Approximately half of patients had a single artery treated. Arterial segments undergoing intervention were femoral-popliteal (48%), aortoiliac (27%), and infrapopliteal (25%).

Dialysis the Common Denominator

Technical success was 92%, with failure to cross the lesion and residual stenosis > 30% each occurring in 4% of cases. Complications included access-site hematoma (5.0%) or occlusion (0.3%) and distal embolization (2.3%). At 30 days, rates of mortality and major amputation were 2.8% and 2.0%, respectively. Reintervention, whether open or percutaneous, was needed in 8.0% of patients within 1 year.

On multivariable Cox analysis, 7 factors were identified as independent predictors of increased 1-year mortality (table 1).

The single factor that predicted a lower mortality risk was independent ambulation prior to intervention (adjusted HR 0.7; 95% CI 0.6-0.9).  

Dialysis dependence, not living at home preoperatively, and congestive heart failure also were associated with worse amputation-free survival, along with tissue loss, male sex, and treatment of certain arterial segments.

Additionally, 5 factors independently predicted major amputation at 1 year (table 2).

Conversely, being a current or former smoker was tied to a lower risk of major amputation (adjusted HR 0.6; 95% CI 0.4-1.0).

Poor Outcomes ‘Sobering’

According to the authors, the “relative paucity of quality outcome data” further complicates the decision-making process when it comes to choosing appropriate treatment in CLI patients, making it important to identify predictors of poor outcomes.

While previous studies have shown some of the same predictive factors after lower-extremity bypass, the current study highlights important differences, Dr. Bertges and colleagues say. Furthermore, the only risk factor common to reduced 1-year survival, amputation-free survival, and freedom from amputation was dialysis. This finding, they say, emphasizes the importance of renal function to prognosis.

“In our study the poor outcomes in patients on dialysis was particularly sobering, with mortality rates of 44% at 1 year,” they note.

They add that a matched comparison of patients from peripheral vascular intervention and lower-extremity bypass registries “may further elucidate the survival difference between patients undergoing open and endovascular revascularization.”

Source: 
Vierthaler L, Callas PW, Goodney PP, et al. Determinants of survival and major amputation after peripheral endovascular intervention for critical limb ischemia. J Vasc Surg. 2015;Epub ahead of print. 

Disclosure:

• Dr. Bertges reports no relevant conflicts of interest. 

Related Stories:

• German Database: Poor Prognosis of Critical Limb Ischemia Patients Linked in Part to Undertreatment
• Endovascular Therapy Promising for Critical Limb Ischemia
• OLIVE: Endovascular Treatment Shows Positive Results for Critical Limb Ischemia

...

Men with systemic lupus erythematosus were more likely to have renal involvement, higher disease activity, accrual of organ damage and higher mortality compared with women with the disease, according to research in a Mexican population.

A cohort of 131 patients with systemic lupus erythematosus (SLE) presenting between 2011 and 2014 was studied. All patients met at least four of the Systemic Lupus Collaborating Clinics (SLICC) 2014 criteria. Eleven of the patients were men, with a female-to-male ratio of 11:1. The mean age of women was 38.9 years, and the mean age of men was 40.6 years. Average disease duration in women was 7.08 years compared with 6.55 years in men.

Univariate analysis showed men with SLE were more likely to have a lower level of education than women with SLE and more likely to have renal involvement, active disease, cumulative damage to organs and higher mortality rates. Men with SLE were also more likely to present peripheral vascular disease and arterial hypertension and to more commonly receive maximum doses of glucocorticoids, mycophenolate mofetil, cyclophosphamide or rituximab, according to the researcher.

The presence of anti-Ro and lupus anticoagulant antibodies was also more likely to be seen in men with SLE compared with women. – by Shirley Pulawski

Reference:

Hermosillo LD. Paper #AB0588. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.

Disclosure: Hermosillo reports no relevant financial disclosures.

...